Ace investor Vijay Kedia acquired a significant stake in Mahamaya Lifesciences through a block deal. He purchased nearly 9 lakh shares at Rs 140 each. This transaction highlights investor interest in the agrochemical firm. Mahamaya Lifesciences manufactures pesticide formulations and crop protection products. The company has shown strong financial growth recently. Its shares have performed well since their market debut.
India set for real GDP growth of 7.5% as inflation stays cool: Axis Bank chief economist Neelkanth Mishra
Axis Bank chief economist Neelkanth Mishra projects India’s real GDP to grow 7.5% in the next fiscal, driven by reforms and supportive policies. Headline inflation